# Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

> **NCT00175019** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 1086 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Febuxostat
- **DRUG:** Febuxostat
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT00175019
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 1086 (ACTUAL)
- **Last updated:** 2010-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175019, "Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00175019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*